Is PCVX or PVLA more profitable?

Vaxcyte's return on equity of -32.51% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Palvella Therapeutics N/A -56.87% -42.50%

Does the media refer more to PCVX or PVLA?

In the previous week, Palvella Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Palvella Therapeutics and 7 mentions for Vaxcyte. Palvella Therapeutics' average media sentiment score of 0.61 beat Vaxcyte's score of -0.25 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or PVLA more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Palvella Therapeutics N/A -56.87% -42.50%

Does the media refer more to SYRE or PVLA?

In the previous week, Spyre Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.61 beat Spyre Therapeutics' score of 0.44 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or PVLA?

In the previous week, Palvella Therapeutics had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Palvella Therapeutics and 5 mentions for Rhythm Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PVLA or ABVX more profitable?

Palvella Therapeutics' return on equity of -56.87% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Palvella Therapeutics N/A -56.87% -42.50% Abivax N/A -99.02% -70.26%

Does the media prefer PVLA or ABVX?

In the previous week, Palvella Therapeutics had 6 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Palvella Therapeutics and 2 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Palvella Therapeutics' score of 0.61 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PVLA or MIRM?

In the previous week, Palvella Therapeutics had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 8 mentions for Palvella Therapeutics and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.18 beat Palvella Therapeutics' score of 0.61 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Palvella Therapeutics (PVLA) Competitors

$151.69 +3.48 (+2.35%)

As of 03:29 PM Eastern

Compare

PVLA vs. PCVX, SYRE, RYTM, ABVX, and MIRM

Should you buy Palvella Therapeutics stock or one of its competitors? MarketBeat compares Palvella Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palvella Therapeutics include Vaxcyte (PCVX), Spyre Therapeutics (SYRE), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Palvella Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Palvella Therapeutics had 1 more articles in the media than Vaxcyte. MarketBeat recorded 8 mentions for Palvella Therapeutics and 7 mentions for Vaxcyte. Palvella Therapeutics' average media sentiment score of 0.61 beat Vaxcyte's score of -0.25 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Palvella Therapeutics has higher revenue and earnings than Vaxcyte. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Palvella Therapeutics	$42.81M	50.81	-$41.72M	-$4.17	N/A

Vaxcyte's return on equity of -32.51% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Vaxcyte presently has a consensus target price of $86.00, indicating a potential upside of 50.17%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 31.54%. Given Vaxcyte's higher possible upside, research analysts plainly believe Vaxcyte is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Palvella Therapeutics beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Spyre Therapeutics presently has a consensus price target of $95.83, suggesting a potential upside of 6.52%. Palvella Therapeutics has a consensus price target of $199.53, suggesting a potential upside of 31.54%. Given Palvella Therapeutics' higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	8,778.74	-$155.20M	-$2.08	N/A
Palvella Therapeutics	$42.81M	50.81	-$41.72M	-$4.17	N/A

Spyre Therapeutics' return on equity of -42.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Spyre Therapeutics has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Spyre Therapeutics and 8 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.61 beat Spyre Therapeutics' score of 0.44 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Spyre Therapeutics beats Palvella Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Palvella Therapeutics (NASDAQ:PVLA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Palvella Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Palvella Therapeutics' return on equity of -56.87% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Palvella Therapeutics	N/A	-56.87%	-42.50%

Palvella Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$217.17M	34.31	-$196.54M	-$3.13	N/A
Palvella Therapeutics	$42.81M	50.81	-$41.72M	-$4.17	N/A

40.1% of Palvella Therapeutics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Palvella Therapeutics had 3 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Palvella Therapeutics and 5 mentions for Rhythm Pharmaceuticals. Palvella Therapeutics' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals currently has a consensus price target of $133.13, indicating a potential upside of 22.44%. Palvella Therapeutics has a consensus price target of $199.53, indicating a potential upside of 31.54%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Summary

Palvella Therapeutics beats Rhythm Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Abivax?

Palvella Therapeutics (NASDAQ:PVLA) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Palvella Therapeutics' return on equity of -56.87% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Abivax	N/A	-99.02%	-70.26%

Palvella Therapeutics has higher revenue and earnings than Abivax. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.81	-$41.72M	-$4.17	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Palvella Therapeutics has a beta of -0.14, suggesting that its share price is 114% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 6 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Palvella Therapeutics and 2 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Palvella Therapeutics' score of 0.61 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics currently has a consensus target price of $199.53, indicating a potential upside of 31.54%. Abivax has a consensus target price of $130.08, indicating a potential upside of 35.69%. Given Abivax's higher possible upside, analysts clearly believe Abivax is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Palvella Therapeutics beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Palvella Therapeutics (NASDAQ:PVLA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

In the previous week, Palvella Therapeutics had 4 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 8 mentions for Palvella Therapeutics and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.18 beat Palvella Therapeutics' score of 0.61 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palvella Therapeutics has a beta of -0.14, meaning that its stock price is 114% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

40.1% of Palvella Therapeutics shares are held by institutional investors. 17.2% of Palvella Therapeutics shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics presently has a consensus price target of $199.53, suggesting a potential upside of 31.54%. Mirum Pharmaceuticals has a consensus price target of $139.80, suggesting a potential upside of 13.54%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Palvella Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	$42.81M	50.81	-$41.72M	-$4.17	N/A
Mirum Pharmaceuticals	$521.31M	14.40	-$23.36M	-$13.61	N/A

Palvella Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Palvella Therapeutics beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PVLA vs. The Competition

Export

Metric	Palvella Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.17B	$3.65B	$6.84B	$12.43B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-36.29	21.21	25.82	24.32
Price / Sales	50.81	343.70	549.62	102.11
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	64.28	8.66	10.98	6.49
Net Income	-$41.72M	$23.92M	$3.58B	$336.61M
7 Day Performance	27.64%	3.71%	2.85%	0.76%
1 Month Performance	28.05%	1.20%	0.52%	-0.48%
1 Year Performance	587.00%	68.53%	36.24%	30.79%

Palvella Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PVLA Palvella Therapeutics	3.0177 of 5 stars	$151.69 +2.3%	$199.53 +31.5%	+571.2%	$2.17B	$42.81M	N/A	N/A
PCVX Vaxcyte	2.0222 of 5 stars	$53.62 -0.5%	$86.00 +60.4%	+73.5%	$7.74B	N/A	N/A	160	Insider Trade Options Volume
SYRE Spyre Therapeutics	1.6779 of 5 stars	$88.67 +2.8%	$95.83 +8.1%	+477.5%	$7.70B	$890K	N/A	73	News Coverage Insider Trade
RYTM Rhythm Pharmaceuticals	2.5856 of 5 stars	$108.39 +0.8%	$133.13 +22.8%	+75.1%	$7.43B	$189.76M	N/A	140
ABVX Abivax	2.947 of 5 stars	$92.26 -0.3%	$130.08 +41.0%	+1,217.6%	$7.36B	N/A	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Palvella Therapeutics (PVLA) Competitors

PVLA vs. PCVX, SYRE, RYTM, ABVX, and MIRM

How does Palvella Therapeutics compare to Vaxcyte?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Palvella Therapeutics compare to Abivax?

Summary

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Palvella Therapeutics (PVLA) Competitors

PVLA vs. PCVX, SYRE, RYTM, ABVX, and MIRM

How does Palvella Therapeutics compare to Vaxcyte?

Does the media refer more to PCVX or PVLA?

Which has more risk and volatility, PCVX or PVLA?

Which has stronger valuation & earnings, PCVX or PVLA?

Is PCVX or PVLA more profitable?

Do analysts recommend PCVX or PVLA?

Do insiders and institutionals believe in PCVX or PVLA?

Summary

How does Palvella Therapeutics compare to Spyre Therapeutics?

Do analysts prefer SYRE or PVLA?

Which has higher valuation & earnings, SYRE or PVLA?

Is SYRE or PVLA more profitable?

Which has more risk & volatility, SYRE or PVLA?

Do institutionals and insiders have more ownership in SYRE or PVLA?

Does the media refer more to SYRE or PVLA?

Summary

How does Palvella Therapeutics compare to Rhythm Pharmaceuticals?

Is RYTM or PVLA more profitable?

Which has stronger valuation & earnings, RYTM or PVLA?

Do institutionals & insiders believe in RYTM or PVLA?

Does the media prefer RYTM or PVLA?

Do analysts prefer RYTM or PVLA?

Which has more risk and volatility, RYTM or PVLA?

Summary

How does Palvella Therapeutics compare to Abivax?

Do insiders & institutionals believe in PVLA or ABVX?

Is PVLA or ABVX more profitable?

Which has better valuation and earnings, PVLA or ABVX?

Which has more risk and volatility, PVLA or ABVX?

Does the media prefer PVLA or ABVX?

Do analysts rate PVLA or ABVX?

Summary

How does Palvella Therapeutics compare to Mirum Pharmaceuticals?

Does the media prefer PVLA or MIRM?

Which has more risk & volatility, PVLA or MIRM?

Do insiders and institutionals hold more shares of PVLA or MIRM?

Do analysts recommend PVLA or MIRM?

Which has preferable valuation and earnings, PVLA or MIRM?

Is PVLA or MIRM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA vs. The Competition

Palvella Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools